The overall 5-year survival rate for cancer in the United States is 70.5%, based on the most recent data from the National Cancer Institute covering 2016 to 2022. That number combines every type of cancer into a single figure, which means it smooths over enormous differences between individual cancers. Some have survival rates above 95%, while others remain below 15%.
Understanding what that number actually means, how it varies by cancer type, and what drives it up or down gives you a much clearer picture than any single statistic can.
What “5-Year Relative Survival” Actually Means
Most cancer survival statistics you’ll encounter are “5-year relative survival rates.” This isn’t just the percentage of cancer patients alive five years after diagnosis. It’s a comparison: the survival of people with cancer measured against the expected survival of similar people in the general population who don’t have cancer. This adjustment accounts for deaths from other causes like heart disease or accidents, isolating the effect of the cancer itself. A 5-year relative survival rate of 70.5% means that, as a group, people diagnosed with cancer are about 70.5% as likely to be alive five years later as people of the same age and sex without cancer.
These rates are also based on people diagnosed years ago, since tracking five years of outcomes requires historical data. Treatments available today may produce better results than these numbers reflect.
How Survival Differs by Cancer Type
The gap between the most survivable and least survivable cancers is striking. Prostate cancer has a 5-year relative survival rate of 98.2%. Breast cancer in women sits at 99.3% when caught before it spreads beyond the breast. These are among the most commonly diagnosed cancers, which is one reason the overall survival figure is as high as it is.
On the other end of the spectrum, pancreatic cancer has a 5-year relative survival rate of just 13.7%. Small cell lung cancer, the more aggressive form, has a combined survival rate of only 9%. These cancers tend to be diagnosed later and respond less predictably to treatment.
Colorectal cancer falls somewhere in between. When caught early and confined to the colon or rectum, the 5-year survival rate is 91.3%. Non-small cell lung cancer, the more common form of lung cancer, has an overall 5-year survival rate of 32%, but that rises to 67% for localized cases.
Why Stage at Diagnosis Matters So Much
Across nearly every cancer type, the single biggest factor separating high survival from low survival is how far the cancer has spread when it’s first found. Cancers are generally grouped into three stages for statistical purposes: localized (still confined to the organ where it started), regional (spread to nearby lymph nodes or tissues), and distant (spread to other parts of the body).
The pattern is consistent and dramatic:
- Breast cancer: 99.3% localized, 86.3% regional, 31% distant
- Prostate cancer: 100% localized, 100% regional, 40.1% distant
- Non-small cell lung cancer: 67% localized, 40% regional, 12% distant
- Colorectal cancer: 91.3% localized, 16.9% distant
For prostate and breast cancers, localized disease is essentially as survivable as not having cancer at all. But once any cancer reaches distant organs, survival drops sharply. This is the core reason screening programs for breast, colorectal, prostate, and lung cancers exist: catching cancer before it spreads changes the math entirely.
Childhood Cancer Survival
Children and adolescents with cancer generally fare better than adults. The 5-year survival rate for children ages 1 to 4 is 87.8%, and it stays in the mid-to-high 80s through adolescence, with 15- to 19-year-olds at 87.3%. Even infants under age 1 have a survival rate of 83.2%. The types of cancer children develop, such as leukemias and brain tumors, are biologically different from most adult cancers and often respond well to treatment.
What Else Affects Your Prognosis
Stage at diagnosis is the most powerful predictor, but it’s far from the only one. The type and location of the cancer matters in ways that go beyond just the organ involved. How abnormal the cancer cells look under a microscope, known as the tumor grade, gives doctors clues about how aggressively the cancer is likely to behave. A low-grade tumor that closely resembles normal tissue typically grows more slowly than a high-grade one.
Certain biological traits of the cancer cells also play a role. Some breast cancers, for example, have receptors for hormones like estrogen, which makes them responsive to targeted therapies that block those hormones. Specific genetic mutations in tumors can open the door to newer precision treatments or, in some cases, signal a more resistant cancer. Your age, overall health before diagnosis, and how well the cancer responds to initial treatment all factor into the picture as well.
This is why two people with the same cancer type and stage can have very different outcomes. Survival statistics describe large groups. They can’t predict what will happen to any individual.
How Far Survival Rates Have Come
The overall cancer survival rate has improved substantially over the past five decades. In the mid-1970s, the 5-year relative survival for all cancers combined was 49%. Today it’s above 70%. That 20-plus-percentage-point gain reflects decades of progress in earlier detection, surgical techniques, chemotherapy regimens, radiation precision, and the introduction of immunotherapy and targeted treatments.
The improvement hasn’t been evenly distributed. Cancers like childhood leukemia and testicular cancer saw dramatic gains decades ago. Others, like pancreatic cancer, have improved more modestly, though even pancreatic cancer survival has roughly doubled from where it was in the 1990s. Lung cancer survival has also been climbing in recent years as screening with low-dose CT scans catches more cases early and newer treatments extend life for advanced disease.